|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
MRP1 silencing in GBM tumour using MRP1-siRNA loaded pSiNPs was demonstrated in mice (82% reduction at the protein level 48 h post-injection), and it also produced antiproliferative effect in GBM by reducing the population of proliferative cells.
|
29653579 |
2018 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
FK506 Attenuates the MRP1-Mediated Chemoresistant Phenotype in Glioblastoma Stem-Like Cells.
|
30208561 |
2018 |
|
Glioblastoma Multiforme
|
0.600 |
PosttranslationalModification
|
disease |
BEFREE |
YWHAG was able to accelerate the phosphorylation of MDM4 and lead to the degradation of P53, which provides a potential mechanism for the tumor-promoting role of miR-217 in glioblastoma cells.
|
28126486 |
2017 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Pomolic acid induces apoptosis and inhibits multidrug resistance protein MRP1 and migration in glioblastoma cells.
|
28849227 |
2017 |
|
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Human CD9 (TSPAN29/MRP-1), a close homolog of tsp2A, was found to be expressed in glioma cell lines A172 and U343MG as well as in the majority of glioblastoma samples (16/22, 73 %).
|
26224160 |
2015 |
|
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
MDM4 and USP2a, as well as the MDM4-USP2a complex, were more highly expressed in glioblastoma multiforme tissue samples from patients with good prognosis compared with patients with poor prognosis.
|
24445145 |
2014 |
|
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
This GBM chemosensitization was caused by a decrease in the expression and activity of the multiple drug associated protein 1 (Mrp1), the most important transporter conferring multiple drug resistance in these cells.
|
22833450 |
2013 |
|
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We conclude that chemosensitization of cells with inhibitors of Mrp1 activity might be an efficient tool for the treatment of human GBM.
|
21544552 |
2011 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
CTD_human |
In summary, HDMX exhibits bona fide oncogenic properties and offers a promising molecular target for GBM therapeutic intervention.
|
20472715 |
2010 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
In summary, HDMX exhibits bona fide oncogenic properties and offers a promising molecular target for GBM therapeutic intervention.
|
20472715 |
2010 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
In conclusion, after Etoposide intervention glioblastoma stem-like cells showed a stronger resistance to apoptosis and death, and the anti-apoptotic gene livinbeta was more related with the high survival rate and MRP1 appeared to be more related with transporting chemotherapeutics out of glioblastoma stem-like cells.
|
20388502 |
2010 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
Univariate analysis of collected data demonstrated that the expressions of O(6)-MGMT and MRP-1 detected by immunohistochemistry, in addition to the consistent factors, including preoperative Karnofsky performance scale (KPS), radical surgery, and tumor location and extension, were significant prognostic factors for the overall survival (OS) of patients with glioblastoma, who received nimustine (ACNU)-based chemotherapy in association with surgery and radiotherapy.
|
19019175 |
2009 |
|
Glioblastoma Multiforme
|
0.600 |
Biomarker
|
disease |
BEFREE |
The properties of glioblastoma and astrocytoma stem-like cells on anti-apoptotic and MRP genes are: anti-apoptotic gene livin and survivin are elevated in CSCs but are the most increased in just differentiated CSCs; MRP1 gene is significantly increased and MRP3 is decreased in CSCs, but when differentiating the MRP3 gene starts a remarkable increase in CSCs; the expression of anti-apoptotic and MRP genes shows no differences between the CSCs isolated from glioblastoma and astrocytoma tissues.
|
18462887 |
2008 |
|
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Brain vessels extracted from tissue sections of nonmalignant human brain and glioblastoma tumors by laser capture microdissection microscopy and analyzed by real-time polymerase chain reaction showed higher expression of ABCG2 relative to ABCB1/MDR1 and ABCC1/MRP1.
|
12958161 |
2003 |
|
Glioblastoma Multiforme
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, our results that exhibit protein expression of MRP1 and MRP3 and gene expression of MRP4 and MRP5 in these 2 glioblastoma cell lines suggest new mechanisms that could lead to a MDR phenotype of tumour cells in patients with glioblastoma multiforme.
|
11857404 |
2002 |
|
Glioblastoma Multiforme
|
0.600 |
GenomicAlterations
|
disease |
CGI |
|
|
|
|
Malignant neoplasm of breast
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Over-expression of FSIP1 promotes breast cancer progression and confers resistance to docetaxel via MRP1 stabilization.
|
30814489 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this work was to assess the effect of long- and short-term incubation with daidzein, the second most abundant soy isoflavone and its metabolite equol on the expression and activity of P-glycoprotein, multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) and BCRP in breast cancer cells.
|
29101532 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
MDM2 drives TNBC circulating tumor cells (CTCs) in mice, but the context-dependent influences of MDM2 and MDMX on different subtypes of breast cancers expressing mtp53 have not been determined.
|
30642351 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
This underscores the need for combinatorial approaches with focus on PXR antagonism to improve drug effectiveness in hepatocellular carcinoma.<b>Abbreviations:</b> HCC: Hepatocellular Carcinoma; FDA: Food and Drug Administration; TGF-β: Transforming growth factor-β; PXR: Pregnane X receptor; CAR: Constitutive androstane receptor; P-gp/ABCB1: P-glycoproteins/ATP-binding cassette transporter subfamily B member 1; MRP1/ABCC1 and MRP2/ABCC2: Multidrug-resistance associated proteins; BCRP/ABCG2: Breast cancer resistant protein; DMEs: Drug-metabolizing enzymes; CFDA: 5,6-carboxyfluorescein diacetate; ETS1: Transcription factor E26 transformation specific sequence 1.
|
31739702 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Correlations of MRP1 gene with serum TGF-β1 and IL-8 in breast cancer patients during chemotherapy.
|
30570851 |
2019 |
|
Malignant neoplasm of breast
|
0.500 |
Biomarker
|
disease |
BEFREE |
Contemplations, using the available literature, suggest that disrupting the stability and/or function of MDMX protein (and its downstream targets), in the context of mtp53 expressing BCs, might be beneficial for patient survival.
|
31489110 |
2019 |
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The aim of this work was to assess the effect of long- and short-term incubation with daidzein, the second most abundant soy isoflavone and its metabolite equol on the expression and activity of P-glycoprotein, multidrug resistance-associated proteins 1 and 2 (MRP1 and MRP2) and BCRP in breast cancer cells.
|
29101532 |
2019 |
|
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Genes encoding proteins that have key functions in the DNA damage response, such as p53 and its inhibitors MDM2 and MDMX, are most likely candidates to harbor allelic variants that influence breast cancer susceptibility.
|
30956778 |
2019 |